There is no evidence of an association between research and development costs and prices of prescription drugs

From JAMA: “Although prices are often justified by the high cost of drug development, there is no evidence of an association between research and development costs and prices ; rather, prescription drugs are priced in the United States primarily on the basis of what the market will bear”. And I guess most pharma executives believe the market can bear a lot more. Continue reading

Why does pharma ignore caregivers?

KEY TAKEAWAY: Almost 45 million American adults provided informal (unpaid) care.  Over half of caregivers are female (60%) while caregiving can take an enormous toll on caregivers.  For example, a Stanford Medicine study that showed 40 percent of Alzheimer’s caregivers die before their patient, “not from disease, but from the sheer physical, spiritual and emotional toll of caring for a loved one with Alzheimer’s. Continue reading

Do you have the courage to be the voice of the patient?

KEY TAKEAWAY: It’s time to change the perception of “big pharma” and show the public that the drugs we develop can save lives without forcing patients to declare bankruptcy.  You have to be the voice of the patient and caregivers in meetings and remind everyone that all though we’re a business our business allows people to live longer, productive lives. Continue reading

DTC: More targeted ads?

KEY TAKEAWAY:Per STAT news “in 2016, the most recent year in which data are available, spending on drug ads reached an estimated $7.6 billion, counting both traditional and digital channels.  Most that money still goes to TV and print, the industry’s old stalwarts for reaching a mass audience”. Allergan pointed to the company’s historically large national TV advertising budget as an opportunity for cost-cutting.  Will others follow? Continue reading